Old Web
English
Sign In
Acemap
>
authorDetail
>
Vinny Hayreh
Vinny Hayreh
Janssen Pharmaceutica
Prostate cancer
Medicine
Prednisone
Abiraterone acetate
Targeted therapy
3
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)
2021
Cancer Chemotherapy and Pharmacology
Fred Saad
Kim N. Chi
Neal D. Shore
Julie N. Graff
Edwin M. Posadas
Jean-Baptiste Lattouf
Byron M. Espina
Eugene Zhu
Alex Yu
Anasuya Hazra
Marc De Meulder
Rao N.V.S. Mamidi
Branislav Bradic
Peter St. John Francis
Vinny Hayreh
Arash Rezazadeh Kalebasty
Show All
Source
Cite
Save
Citations (1)
AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).
2021
Journal of Clinical Oncology
Dana E. Rathkopf
Kim N. Chi
David Olmos
Heather H. Cheng
Neeraj Agarwal
Julie N. Graff
Shahneen Sandhu
Vinny Hayreh
Angela Lopez-Gitlitz
Peter St. John Francis
Gerhardt Attard
Show All
Source
Cite
Save
Citations (0)
Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
2020
Journal of Clinical Oncology
Fred Saad
Kim N. Chi
Neal D. Shore
Julie N. Graff
Edwin M. Posadas
Byron M. Espina
Eugene Zhu
Anasuya Hazra
Branislav Bradic
Shinta Cheng
Vinny Hayreh
Arash Rezazadeh
Show All
Source
Cite
Save
Citations (1)
1